Probiotic Protein Fraction Composition for S. Aureus Adhesion Blocking
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
The mechanisms underlying the positive effects of probiotics on skin and mucosal membranes are poorly understood, and existing treatments for skin infections, particularly those caused by Staphylococcus aureus, lack efficacy and specificity.
Innovation Solution
A composition comprising a protein fraction derived from a probiotic lysate, preferably from Lactobacillus rhamnosus, containing proteins up to 100 kDa, including Subtilin biosynthesis protein C (SpaC) and other proteins, which inhibits S. aureus adhesion and enhances keratinocyte survival and migration.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If whole probiotic bacteria are used, then immune stimulation and pathogen inhibition effects are achieved, but safety concerns and regulatory restrictions arise
Solution Approach 1:
The patent extracts the beneficial active components (proteins and peptides) from the whole probiotic bacteria through lysate preparation. This extraction maintains the therapeutic effects of pathogen inhibition and immune modulation while eliminating the safety concerns associated with live bacteria, including concerns about uncontrolled growth and regulatory restrictions on live biotherapeutic products.
Solution Approach 2:
The patent creates a simplified copy of the probiotic mechanism by using purified protein fractions that replicate the key functions of whole bacteria. The protein fractions (including SpaC and other adhesins) copy the adhesion and pathogen inhibition capabilities without requiring live bacterial cells, thus maintaining efficacy while improving safety and regulatory acceptability.
2Reliability
If protein fraction with molecular weight up to 100 kDa is used, then S. aureus adhesion inhibition is achieved, but manufacturing complexity increases
Solution Approach 1:
The patent defines a specific molecular weight parameter range (up to 100 kDa) for the protein fraction to optimize adhesion inhibition efficacy. This parameter-based definition provides a clear manufacturing specification that balances therapeutic effectiveness with manufacturing feasibility, allowing standard protein purification techniques to be used without requiring overly complex separation processes.
Solution Approach 2:
The patent uses a composite approach by combining multiple protein fractions (including SpaC pilin and other adhesins) within the defined molecular weight range. This composite protein fraction achieves synergistic adhesion inhibition effects while maintaining a relatively simple manufacturing process compared to using individual purified proteins.
3Reliability
If live probiotics are used, then competitive exclusion of pathogens occurs, but control over mechanism and consistency of effect is limited
Solution Approach 1:
By extracting and identifying specific proteins (SpaC, Pilus proteins, and other adhesins) from the probiotic lysate, the patent isolates the mechanism of action. This allows researchers to understand exactly which molecular components are responsible for pathogen exclusion, rather than observing only the overall effect of live bacteria.
Solution Approach 2:
The patent replaces the complex biological system of live bacteria with a defined protein fraction system. This substitution allows for better control and understanding of the mechanism, as the protein fractions can be characterized, quantified, and their interactions with pathogens studied in a more controlled manner than whole live bacteria.
Data Source
AI summary
The present invention relates to a composition comprising a probiotic extract, wherein the extract comprises a protein fraction derived from a secretion or lysate and having proteins of a molecular weight of up to 100 kDa. The composition may have a number of uses, such as for use in the prevention, management or treatment of bacterial infection or the enhancement and improvement of skin health.